Practical Considerations for Antibodies in Myeloma

Jacob P. Laubach; Niels van de Donk; Faith E. Davies; Joseph Mikhael

doi:10.1200/EDBK_205443

Practical Considerations for Antibodies in Myeloma

Jacob P. Laubach, Niels van de Donk, Faith E. Davies, Joseph Mikhael

Hematology/Oncology

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

The development of the monoclonal antibodies daratumumab and elotuzumab has expanded treatment options for multiple myeloma and led to great improvement in patient outcomes. These agents have favorable safety profiles and synergize effectively with established agents used in the management of myeloma, namely immunomodulatory drugs and proteasome inhibitors. This article reviews the rationale for use of monoclonal antibodies in myeloma, current approved indications for daratumumab and elotuzumab, the manner in which these agents are used in the overall management of myeloma, and specific challenges associated with their use in the clinic. It also highlights other, emerging drug combinations that incorporate daratumumab or elotuzumab and profiles new therapeutic antibodies currently under development.

Original language	English (US)
Pages (from-to)	667-674
Number of pages	8
Journal	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Issue number	38
DOIs	https://doi.org/10.1200/EDBK_205443
State	Published - May 23 2018

ASJC Scopus subject areas

General Medicine

Access to Document

10.1200/EDBK_205443

Cite this

@article{094a1ef075fb470c83ba52245e05713f,

title = "Practical Considerations for Antibodies in Myeloma",

abstract = "The development of the monoclonal antibodies daratumumab and elotuzumab has expanded treatment options for multiple myeloma and led to great improvement in patient outcomes. These agents have favorable safety profiles and synergize effectively with established agents used in the management of myeloma, namely immunomodulatory drugs and proteasome inhibitors. This article reviews the rationale for use of monoclonal antibodies in myeloma, current approved indications for daratumumab and elotuzumab, the manner in which these agents are used in the overall management of myeloma, and specific challenges associated with their use in the clinic. It also highlights other, emerging drug combinations that incorporate daratumumab or elotuzumab and profiles new therapeutic antibodies currently under development.",

author = "Laubach, {Jacob P.} and {van de Donk}, Niels and Davies, {Faith E.} and Joseph Mikhael",

year = "2018",

month = may,

day = "23",

doi = "10.1200/EDBK_205443",

language = "English (US)",

pages = "667--674",

journal = "American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting",

issn = "1548-8756",

publisher = "American Society of Clinical Oncology",

number = "38",

}

TY - JOUR

T1 - Practical Considerations for Antibodies in Myeloma

AU - Laubach, Jacob P.

AU - van de Donk, Niels

AU - Davies, Faith E.

AU - Mikhael, Joseph

PY - 2018/5/23

Y1 - 2018/5/23

N2 - The development of the monoclonal antibodies daratumumab and elotuzumab has expanded treatment options for multiple myeloma and led to great improvement in patient outcomes. These agents have favorable safety profiles and synergize effectively with established agents used in the management of myeloma, namely immunomodulatory drugs and proteasome inhibitors. This article reviews the rationale for use of monoclonal antibodies in myeloma, current approved indications for daratumumab and elotuzumab, the manner in which these agents are used in the overall management of myeloma, and specific challenges associated with their use in the clinic. It also highlights other, emerging drug combinations that incorporate daratumumab or elotuzumab and profiles new therapeutic antibodies currently under development.

AB - The development of the monoclonal antibodies daratumumab and elotuzumab has expanded treatment options for multiple myeloma and led to great improvement in patient outcomes. These agents have favorable safety profiles and synergize effectively with established agents used in the management of myeloma, namely immunomodulatory drugs and proteasome inhibitors. This article reviews the rationale for use of monoclonal antibodies in myeloma, current approved indications for daratumumab and elotuzumab, the manner in which these agents are used in the overall management of myeloma, and specific challenges associated with their use in the clinic. It also highlights other, emerging drug combinations that incorporate daratumumab or elotuzumab and profiles new therapeutic antibodies currently under development.

UR - http://www.scopus.com/inward/record.url?scp=85056029998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056029998&partnerID=8YFLogxK

U2 - 10.1200/EDBK_205443

DO - 10.1200/EDBK_205443

M3 - Review article

C2 - 30231321

AN - SCOPUS:85056029998

SN - 1548-8756

SP - 667

EP - 674

JO - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

JF - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

IS - 38

ER -

Practical Considerations for Antibodies in Myeloma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this